Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease

Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image

Wei Shen, Mark Punyanitya, ZiMian Wang et al. · Journal of Applied Physiology · 2004 · 1.7K citations

Medicine, Physiology, Radiology +17

Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

Carla M. Prado, Vickie E. Baracos, Linda J. McCargar et al. · Clinical Cancer Research · 2009 · 1.1K citations

Medicine, Oncology, Pharmacology +17

Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease

Marie C. Hogan, Linda J. Page, Vickie Kubly et al. · Journal of the American Society of Nephrology · 2010 · 333 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Octreotide Inhibits Hepatic Cystogenesis in a Rodent Model of Polycystic Liver Disease by Reducing Cholangiocyte Adenosine 3′,5′-Cyclic Monophosphate

Tatyana V. Masyuk, Anatoliy I. Masyuk, Vicente E. Torres et al. · Gastroenterology · 2006 · 285 citations · Full text

Medicine, Molecular Biology, Pharmacology +17

Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial

Loes van Keimpema, Frederik Nevens, Ragna Vanslembrouck et al. · Gastroenterology · 2009 · 256 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11